Organ On Chip Market: By Technology (Microfluidics-based Organ-on-Chip, 3D Bioprinting-based Organ-on-Chip, Other), By Organ Types ( Liver-on-Chip, Brain-on-Chip, Lung-on-Chip, Heart-on-Chip, Kidney-on-Chip, Other types), By Application (Drug Discovery, Toxicology Research, Physiological Model Development, Disease Modelling, Personalized Medicine), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Cosmetics Industry, Healthcare Providers) and Geography

Organ On Chip Market size was valued at USD 116.4 million in 2023 and is poised to grow at a CAGR of 32.1% from 2024 - 2030. Organ-on-chip (OOC) refers to a technology that replicates the activities, mechanics, and physiological responses of entire organs or organ systems on a microscale device. The primary goal of organ-on-chip technology is to provide a more accurate representation of human physiology compared to traditional cell cultures and animal models. There is a growing demand for alternatives to animal testing in pharmaceutical and biotechnology industries. Organ-on-chip technology offers a more ethical and accurate approach to studying human physiology and disease mechanisms compared to traditional methods.

Moreover, continuous technological advancements, such as 3D bioprinting, microfluidics, and sensor integration are the convenience provided by using this product are enhancing the capabilities and applicability of organ-on-chip models. These advancements improve the accuracy, efficacy, reproducibility, and complexity of organ-on-chip systems, making them more reliable for drug testing and disease modelling. Adding to that, FDA's interest in advancing organ-on-chip technology also plays as an important driver for this market. Although, it’s welcomed the initial investment and operational costs associated, technological complexity, validation standardization of organ-on-chip models across different laboratories, and limited interoperability between different organ-on-chip systems remain as hurdles to the market. Even though it offers an ethical advantage, when it comes to using of human cells ethical considerations and regulatory requirements for approval, pose challenges. There is also increasing pressure from society and governments to find alternatives to animal testing, as evidenced by the US Food and Drug Administration (FDA) Modernization Act of 2021 and the Humane Research and Testing Act (HR 1744). The FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program, which has established similar qualification programs for drug development tools, including organ chips

Organ On Chip Market Key Developments:

• In April 2024, CN Bio Innovations Ltd. secured $21 million in the initial closing of its Series B investment round and was chosen for the NC3Rs SensOoChip Challenge, tasked with developing advanced Heart-on-Chip technology.
• In January 2024, CN Bio Innovations Ltd. and Altis Biosystems joined forces to develop a human gut/liver in vitro model for advanced absorption, distribution, metabolism, and excretion (ADME) studies.